安博诺和安博维治疗原发性高血压病的临床疗效对比观察  

作　　者：余文浩 范国权 

机构地区：[1]广东省干部疗养院,510970

出　　处：《当代医学》2010年第16期64-66,共3页Contemporary Medicine

摘　　要：目的观察安博诺和安博维治疗原发性轻、中度高血压患者的临床疗效与安全性。方法采用随机对照方法 ,观察安博诺(65例)每日150/12.5mg与安博维(60例)每日150mg对治疗轻、中度高血压患者12周的有效率。结果两组收缩压(SBP)、舒张压(DBP)和心率(HR)较治疗前明显降低(P<0.05)。4～12周安博诺组血压下降值为13.7/12.2～21.5/16mmHg,安博维组为13.0/12.2～17.8/15.2mmHg,安博诺和安博维治疗12周降低血压的总有效率分别为90.8%和81.7%(P<0.05)。结论安博诺对原发性轻、中度高血压患者治疗效果优于安博维。Objective To determine the therapeutic effect and define the safety profile of Irbesartan and Hydrochlorothiazide Tablets（Coaprovel） and Irbesartan Tablets （Aprovel） when used in mild and moderate primary hypertension. Methods 125 patients with mild and moderate primary hypertension were randomized and received Irbesartan and Hydroehlorothiazide Tablets （150/12.Smg/day, peros, n=65） and Irbesartan Tablets （150rag/day, peros, n--60）. All patients were administrated orally and observed seriately for 12 weeks. Results Reductions in systolic blood pressure （SBP）, diastolic blood pressure （DBP） and heart rate （HR） was observed in two group （P〈0.05）. After 4 to 12 weeks＇ treatment, Irbesartan and Hydrochlorothiazide Taolets low BP by 13.7/12.2-21.5/16mmHg, and Irbesartan Tablets low BP by 17.8/15.2mmHg. Overall, after 12 weeks＇ treatment, 91.3% of patients in Irbesartan and Hydrochlorothiazide Tablets group achieved their dual SBP/DBP goal, while81.1% of patients in Irbesartan Tablets group achieve their dual SBP/DBP goal.（P〈0.05）. Conclusion Irbesartan and Hydrochlorothiazide Tablets is more effective in mild and moderate primary hypertension patients than Irbesartan Tablets.

关 键 词：高血压 安博诺 安博维 

分 类 号：R544.1[医药卫生—心血管疾病]